NCT05207397Completed
Lactate for Energy and Neurocognition
Source: ClinicalTrials.gov · Last updated 14 May 2025
Brief summary (registry, in English)
Improved cardiorespiratory fitness following an aerobic exercise program elicits cognitive benefit in elderly subjects and memory improvement in Alzheimer's disease (AD). The physiological mechanism may be related to exercise-mediated change in circulating factors that permeate the brain. The response to each individual bout of exercise (i.e. the acute exercise response) may differ between subjects and be key to driving brain benefit. In young populations, the acute response to exercise can last hours and affect brain glucose metabolism. However, the field knows little about this acute exercise response in AD. Most exercise intervention trials designed to prevent and slow AD assess biomarkers at two fasting time points: pre- and post-intervention. The acute exercise response in the brain and periphery likely varies between subjects and diagnoses and provide key information regarding mechanisms of benefit. Our primary goals are to characterize the acute exercise response to exercise in the brain (glucose metabolism) and periphery (biomarker response) in aging and AD. We will identify relationships between exercise-related factors (i.e. heart rate, biomarkers) and change in brain metabolism and cognition. Understanding these mechanistic relationships will provide specific targets that can be used in future trials to develop individualized exercise prescriptions and maximize benefit.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 24 (actual)
- First submitted
- 9 Aug 2021
- Start date
- 12 Apr 2023
- Primary completion date
- 29 Mar 2024
- Lead sponsor
- University of Kansas Medical Center
- Diseases
- Alzheimer disease
- NCT number
- NCT05207397
What you commit to
- Study type: Observational
- Participants enrolled: 24
- From 12 Apr 2023 to the primary completion date, 29 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diagnosis of insulin-dependent (Type 1) Diabetes Mellitus
- Diagnosis of a clinically significant chronic disease including CVD, other metabolic diseases (e.g., thyroid), cancer, HIV, or acquired immunodeficiency syndrome
- Any Neurological disorders that have the potential to impair cognition or brain metabolism (e.g., Parkinson's disease, stroke defined as a clinical episode with neuroimaging evidence in an appropriate area to explain the symptoms).
- Clinically significant depressive symptoms that may impair cognition, abnormalities in B12, RPR, or thyroid function that may impair cognition, use of psychoactive and investigational medications, and significant visual or auditory impairment
Lab values
- Anti-platelet medication (Plavix), Warfarin, and other anticoagulants (Eliquis, Pradaxa, and Xarelto)
Age
- Recent ischemic heart disease (\<2 years)
Other
- Inability to provide consent
Who the study is looking for
- Age 60 and older
- Stable medication doses (\>1month)
- Post-menopausal
- Diagnosis of either Nondemented (CDR 0) or Probable AD (CDR 0.5 or 1 only)
Age in the registry: 60 years to 95 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Univeristy of Kansas Medical Center Coordinator of this site? Confirm its status | Kansas City | United States | Unknown status |
Related publications
- Acute effects of lactate infusion on metabolism, AD biomarkers, and cognition: The LEAN study.Alzheimers Dement · 2025 · PMID 41376120
This page is information, not medical advice. Discuss any trial with your doctor.